Neonc Technologies Holdings, INC

NeOnc Technologies announced positive top-line results from the Phase 2a portion of its NEO100-01 clinical trial for recurrent IDH1 mutant high-grade glioma, demonstrating a significant improvement in overall survival.

NeOnc Technologies announced positive topline results from the Phase 2a portion of its NEO100-01 study, showing a significant improvement in progression-free survival for patients with recurrent IDH1-mutant glioma.

NeOnc Technologies reported Q2 2026 financial results, confirmed topline data for its Phase 2a NEO100 study to be presented August 12, 2026, and announced international IND approvals.

NeOnc Technologies Holdings, Inc. announced it received written feedback from the FDA regarding the CMC development program for its NEO212 drug candidate, including requirements for a capsule-to-tablet formulation transition.

NeOnc Technologies Holdings, Inc. reports the resignation of a Class II director and the immediate appointment of a new director with extensive strategy and technology experience.

NeOnc Technologies Holdings, Inc. has entered into a securities purchase agreement to raise up to $5 million through the issuance of Series A Convertible Preferred Stock.

NeOnc Technologies Holdings, Inc. has amended its advisory agreement with AFH Holding & Advisory, LLC, establishing a new annual fee structure based on fully diluted market capitalization, while the company continues to grapple with significant operating losses and substantial doubt regarding its ability to continue as a going concern.

NEONC Technologies reported significantly increased net losses in Q3 2025 despite a NASDAQ listing and capital raises, facing substantial doubt about its going concern ability.

NEONC Technologies Holdings, Inc. reported a significantly wider net loss for Q2 2025, driven by increased operating expenses and share-based compensation, while actively pursuing new financing and strategic partnerships.

NeOnc Technologies Holdings reports a substantial net loss for Q1 2025, driven by increased operating expenses, including share-based compensation and advisory fees, despite completing its NASDAQ listing.

NeOnc Technologies Holdings, Inc. files an amendment to its 2025 Form 10-K to include previously omitted Part III information and updated certifications.

Amir F Heshmatpour, CEO, President, a Director and 10% owner of Neonc Technologies Holdings, Inc., purchased 15,000 shares of common stock on August 14, 2026.

Nasim Shomali, a Director of Neonc Technologies Holdings, Inc., received 50,000 shares of common stock on July 10, 2025.

Amir Heshmatpour, a Director and Officer of NEONC TECHNOLOGIES HOLDINGS, INC., reported a significant acquisition of common stock.

Director and President Amir F. Heshmatpour acquired 10,000 shares of NEONC Technologies Holdings, Inc. common stock at $4.518 per share.

Chief Clinical Officer Yousha Neman-Ebrahim purchased 500 shares of NEONC Technologies Holdings, Inc. common stock.

CFO Keithly Garnett purchased 300 shares of NEONC Technologies Holdings, Inc. common stock at a price of $5.38 per share.

NeOnc Technologies Holdings, Inc. reports significant losses and a going concern warning, while advancing multiple brain cancer drug candidates and securing recent financing.

NeOnc Technologies Holdings, Inc. reports significant net losses and an accumulated deficit, raising substantial doubt about its ability to continue as a going concern, despite advancing its lead drug candidates NEO100 and NEO212 in clinical trials and acquiring new AI and 3D bioprinting platforms.

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company focused on brain cancers, has filed an S-1 registration statement to facilitate the resale of shares tied to a potential $50 million equity line of credit, while disclosing significant financial losses and a 'going concern' warning from its auditors.

NeOnc Technologies is registering the resale of up to 5.7 million shares of its common stock by existing stockholders following its direct listing on the Nasdaq Global Market.

NeOnc Technologies Holdings is set to pursue a direct listing on the Nasdaq Global Market, offering 2,101,313 shares for resale by existing stockholders.

NeOnc Technologies has engaged RBW Capital Partners for financial advisory services related to its direct listing on Nasdaq and a private placement of common stock.

Amir F. Heshmatpour and affiliated entities have disclosed a combined beneficial ownership of 34.3% in NeOnc Technologies Holdings, Inc. following the company's direct listing on the Nasdaq Global Market, including a cashless warrant exercise.

Cinctive Capital Management LP and its affiliates have reported a 9.99% beneficial ownership stake in NeOnc Technologies Holdings, Inc. as of March 31, 2026.